Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis
Bayesian network meta-analyses found strong probabilistic evidence supporting the treatment benefit of elafibranor compared with seladelpar for the achievement of cholestasis response at 52 weeks, while the treatment effect on other outcomes was uncertain. Head-to-head studies are needed to validate results of these indirect comparisons.
Authors
- Emily Combe (ORCID: https://orcid.org/0000-0002-0834-6562)
- E. Boing (ORCID: https://orcid.org/0000-0001-5336-501X)
- Shijie Ren (ORCID: https://orcid.org/0000-0003-3568-7124)
- Alex Pashley
- David E. Jones (ORCID: https://orcid.org/0000-0002-0083-5564)
- Vicki Laskier-Owens
- Tom Wright
- Harun Knight
Institutions
- Ipsen (France) (FR)
- NIHR Newcastle Biomedical Research Centre (GB)
- Costello Medical Consulting (United Kingdom) (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Journal of Comparative Effectiveness Research
- Published
- 2026-04-17
- DOI
- https://doi.org/10.57264/cer-2025-0206
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00